此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment (HARMONY)

2026年11月5日 更新者:Travere Therapeutics, Inc.

一项 3 期、平行组治疗、盲法、随机、安慰剂对照研究,旨在评估除标准护理外皮下注射聚乙二醇化酶对因胱硫醚β合酶缺乏症导致的经典同型半胱氨酸尿症参与者的疗效和安全性 (HARMONY)

Researchers are looking for a better way to treat people living with classical homocystinuria (HCU), a rare inherited condition. It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme helps break down homocysteine, which is produced when the body processes methionine from protein-containing foods. This helps keep homocysteine and methionine at healthy levels. When this enzyme is not working, homocysteine and methionine build up in the blood and then spread into different tissues of the body and stop these body tissues from working normally.

People living with HCU can experience problems with their vision, bones, blood vessels, thinking, learning, and memory. Available treatments for HCU include a low-methionine diet (typically achieved by limiting protein-containing foods), a methionine-free protein supplement to help meet daily protein needs, and betaine (Cystadane®). These treatments are either not sufficient or are hard to take for many patients.

Pegtibatinase was designed by researchers to act like the CBS enzyme, which is missing or not working properly in people living with HCU. Researchers are studying whether adding pegtibatinase to standard treatment can lower homocysteine levels.

Researchers want to learn how safe and effective pegtibatinase is, how it moves through and affects the body, and how it may affect the daily lives of people with HCU.

The study plans to enroll participants from the US, Australia, Belgium, France, Germany, Ireland, Italy, Poland, Portugal, Qatar, Saudi Arabia, Spain, Turkey, and the United Kingdom. Many study visits may happen at home, depending on where you live and local regulations. Some visits may include a home nurse and telemedicine appointments with the study doctor.

研究概览

详细说明

Primary Objective:

Researchers want to learn more about how pegtibatinase will affect homocysteine and methionine levels when it is injected under the skin in participants already receiving standard treatment.

Blood tests will be used to measure changes in these levels during the study.

Secondary Objectives:

Researchers also want to learn:

  • Is pegtibatinase safe and tolerable (how does it make participants feel)?
  • How does pegtibatinase move throughout the body?
  • Does pegtibatinase produce antibodies (proteins the body makes that may stop pegtibatinase from working or cause side effects)?
  • How does pegtibatinase affect daily lives of participants with HCU? Researchers will use blood tests, urine tests, physical examinations, and questionnaires to answer these questions.

Study Population and Treatments:

This is a global study will include children and adults from 12 to 65 years old. Participants in the study will take their standard of care treatment. Participants will be put into 1 of 2 groups at random (like the flip of a coin) to take either:

  • pegtibatinase, or
  • an injection that does not have any medicine in it (or "placebo"). These are given as injections under the skin 2 times a week for up to 24 weeks. Neither the researchers nor the participant knows which treatment they are getting until the study is complete.

Study Duration and Visits:

Participants may be in the study for up to 38 weeks, including the screening period of up to 4 weeks, a pre-treatment period of up to 6 weeks where the participants will discuss their current diet with a dietitian (a health professional specialized in nutrition), a blinded treatment period of up to 24 weeks, and a safety follow-up visit completed 4 weeks after the last dose of study medication. Participants who complete the blinded treatment period may qualify to join the ENSEMBLE study before finishing the safety follow-up visit.

Participants who meet all study requirements may have up to 58 study visits. Visits may take place at a study center, at home, or by telemedicine.

These visits can include:

  • Blood and urine tests
  • Physical examinations
  • Questionnaires
  • Injections
  • Questions about how they are feeling or any problems they are having

Safety / Adverse Events:

Researchers will monitor participants for any medical problems that occur during the study. Participants will have regular laboratory tests, health checkups, and study visits to monitor their health and safety.

Benefit-risk Conclusion:

Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.

研究类型

介入性

注册 (估计的)

70

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Doha、卡塔尔
        • 招聘中
        • Hamad General Hospital
      • Doha、卡塔尔
        • 招聘中
        • Sidra Hospital
      • Ankara、土耳其(türkiye)
        • 招聘中
        • Gazi University Hospital
      • Bornova、土耳其(türkiye)
        • 尚未招聘
        • Ege Üniversitesi Hastanesi Bornova
      • Istanbul、土耳其(türkiye)
        • 尚未招聘
        • Istanbul University Cerrahpasa Hospital
      • Hamburg、德国
        • 尚未招聘
        • Universitätsklinikum Hamburg-Eppendorf
      • Leipzig、德国
        • 尚未招聘
        • Universitätsklinikum Leipzig
      • Münster、德国
        • 尚未招聘
        • Universitätsklinikum Münster
      • Bari、意大利
        • 尚未招聘
        • Ospedale Pediatrico Giovanni XXIII
      • Genova、意大利
        • 尚未招聘
        • IRCCS Istituto Giannina Gaslini
      • Milan、意大利
        • 尚未招聘
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Policlinico di Milano)
      • Monza、意大利
        • 尚未招聘
        • Fondazione IRCCS San Gerardo Dei Tintori - Ospedale San Gerardo
      • Padova、意大利
        • 尚未招聘
        • Azienda Ospedaliera di Padova
      • Brussels、比利时
        • 招聘中
        • Cliniques Universitaires Saint-Luc
      • Edegem、比利时
        • 招聘中
        • Universitair Ziekenhuis Antwerpen (UZA)
      • Riyadh、沙特阿拉伯
        • 招聘中
        • King Abdullah International Medical Research Center
      • Riyadh、沙特阿拉伯
        • 招聘中
        • King Faisal Specialist Hospital and Research Centre (KFSHRC) - Riyadh
      • Paris、法国
        • 招聘中
        • Assistance Publique - Hôpitaux de Paris (AP-HP) - Hôpital Necker-Enfants Malades
      • Tours、法国
        • 招聘中
        • CHRU Hôpitaux de Tours - Hôpital Bretonneau
      • Vandœuvre-lès-Nancy、法国
        • 招聘中
        • Centre Hospitalier Régional Universitaire de Nancy (CHRU) - Hopitaux de Brabois - Hôpital d'enfants
      • Krakow、波兰
        • 尚未招聘
        • SP ZOZ Szpital Uniwersytecki w Krakowie
      • Warsaw、波兰
        • 招聘中
        • Instytut Pomnik-Centrum Zdrowia Dziecka
      • Warsaw、波兰
        • 尚未招聘
        • Instytut Matki i Dziecka
      • Adelaide、澳大利亚
        • 招聘中
        • Royal Adelaide Hospital
      • Parkville、澳大利亚
        • 招聘中
        • Royal Children's Hospital Melbourne
      • Westmead、澳大利亚
        • 招聘中
        • Westmead Hospital
      • Dublin、爱尔兰
        • 招聘中
        • Children's Health Ireland (CHI) at Temple Street
    • Arizona
      • Phoenix、Arizona、美国、85006
        • 招聘中
        • Phoenix Children's Hospital
    • Connecticut
      • New Haven、Connecticut、美国、06519
        • 招聘中
        • Yale University School of Medicine
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Emory University
    • Illinois
      • Chicago、Illinois、美国、60611
        • 招聘中
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Maine
      • Portland、Maine、美国、04102
        • 招聘中
        • Maine Health - Maine Medical Center
    • Maryland
      • Chevy Chase、Maryland、美国、20815
        • 招聘中
        • Uncommon Cures
    • New York
      • New York、New York、美国、10029
        • 招聘中
        • The Mount Sinai Hospital
    • North Carolina
      • Morrisville、North Carolina、美国、27560
        • 招聘中
        • Science 37 - Virtual Site
    • Oregon
      • Portland、Oregon、美国、97239
        • 尚未招聘
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Children's Hospital of Philadelphia
      • Pittsburgh、Pennsylvania、美国、15224
        • 招聘中
        • University of Pittsburgh Medical Center - Children's Hospital of Pittsburgh
    • Texas
      • Dallas、Texas、美国、75390
        • 招聘中
        • University of Texas Southwestern Medical Center
    • Utah
      • Salt Lake City、Utah、美国、84113
        • 招聘中
        • Utah Health - The University of Utah Primary Children's Hospital
      • Birmingham、英国
        • 招聘中
        • Birmingham Women's and Children's NHS Foundation Trust
      • Birmingham、英国
        • 招聘中
        • University Hospitals Birmingham NHS Foundation Trust - Queen Elizabeth Hospital Birmingham
      • London、英国
        • 尚未招聘
        • University College London Hospitals NHS Foundation Trust - National Hospital for Neurology and Neurosurgery
      • Salford、英国
        • 招聘中
        • Salford Royal NHS Foundation Trust - Salford Royal Hospital
      • Coimbra、葡萄牙
        • 招聘中
        • Unidade Local de Saúde de Coimbra, EPE - Hospitais da Universidade de Coimbra
      • Lisbon、葡萄牙
        • 招聘中
        • Unidade Local de Saúde de Santa Maria, EPE - Hospital de Santa Maria
      • Porto、葡萄牙
        • 尚未招聘
        • Unidade Local de Saúde de São João, EPE - Hospital São João
      • Barcelona、西班牙
        • 招聘中
        • Hospital Sant Joan de Déu
      • Madrid、西班牙
        • 招聘中
        • Hospital Universitario 12 de Octubre
      • Madrid、西班牙
        • 招聘中
        • Hospital Universitario Ramón y Cajal
      • Santiago de Compostela、西班牙
        • 招聘中
        • Complejo Hospitalario Universitario de Santiago (CHUS) - Hospital Clínico Universitario
      • Seville、西班牙
        • 招聘中
        • Hospital Universitario Virgen del Rocío

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 至 65年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Must be ≥12 to ≤65 years of age, at the time of signing the informed consent
  • Must have a diagnosis of classical HCU based on clinical, biochemical, and/or molecular genetic testing
  • Plasma tHcy ≥80 µM at Screening visit, with allowance for up to 18 participants who may be enrolled with a Screening plasma tHcy ≥50 to <80 µM
  • Participants who can become pregnant must have a negative pregnancy test before starting the study and must use a highly effective form of birth control (less than 1% risk of pregnancy per year) during the study and for at least 4 weeks after the last dose.
  • Willing to maintain a generally stable diet for the duration of the study (unless changes are required based on medical/safety reasons)
  • Willing to maintain generally stable intake and doses of betaine, pyridoxine, and medical food for the duration of the study (unless changes are required based on medical/safety reasons)

Exclusion Criteria:

  • Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or disorder of cobalamin metabolism
  • Concurrent disease or condition (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease) that would interfere with study participation or safety (excluding complications of HCU).
  • History of major thrombotic event (eg, cerebrovascular accident, myocardial infarction, pulmonary embolism) in the previous 6 months.
  • Body weight ≥160 kg.
  • Use or planned use of any injectable drugs containing PEG (excluding PEG-containing vaccines)
  • Any previous exposure to pegtibatinase and/or previous participation in a clinical study that included administration of pegtibatinase or pegtarviliase
  • Prior severe immune reaction to a PEG-containing product

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:安慰剂

volume-matched saline SC BIW

实验性的:聚乙二醇酶

Pegtibatinase BIW

其他名称:
  • TVT-058
  • OT-058

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in plasma tHcy levels - Weeks 6 to 12
大体时间:Weeks 6 - 12

Change between baseline and average of 6 to 12 week (6, 8, 10, and 12 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy

Weeks 6 - 12

次要结果测量

结果测量
措施说明
大体时间
Change from baseline in plasma tHcy levels - Weeks 16 to 24
大体时间:Weeks 16 - 24

Change between baseline and average of 16 to 24 week (16, 20, and 24 week) plasma tHcy levels in participants receiving pegtibatinase vs. placebo. Baseline tHcy level defined as average of Week -3, Week -1, and Day 1 pre-dose plasma tHcy

Weeks 16 - 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Michael Imperiale, MD、Travere Therapeutics, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年12月28日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2024年1月30日

首先提交符合 QC 标准的

2024年1月30日

首次发布 (实际的)

2024年2月7日

研究记录更新

最后更新发布 (实际的)

2026年11月9日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.

IPD 共享时间框架

Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.

IPD 共享访问标准

Requires submission and approval of intended use and a data sharing agreement.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅